Showing results (471-480 of 566) with videos related to

Sort By:
Pageof 57
The Journal of Rheumatology. Supplement|June 3, 2018
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual MeetingRichard Holland, William Tillett, Alexis Ogdie, et al.
The Journal of Rheumatology|August 3, 2017
Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument SetsSean R Tunis, Lara J Maxwell, Ian D Graham, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working GroupYing Ying Leung, Ana-Maria Orbai, William Tillett, et al.
Seminars in Arthritis and Rheumatism|January 23, 2021
Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working groupDorthe B Berthelsen, Thasia G Woodworth, Niti Goel, et al.
Rheumatology (Oxford, England)|December 28, 2018
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisJeffrey R Curtis, Darl D Flake, Michael E Weinblatt, et al.
Zeitschrift Fur Rheumatologie|February 27, 2025
Criteria for the authorisation of specialty training for competence in internal medicine and rheumatology-a position paper of the German Society for Rheumatology and Clinical ImmunologyAlexander Pfeil, Martin Fleck, Martin Aringer, et al.
The Journal of Rheumatology|March 2, 2021
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working GroupYing Ying Leung, Ana-Maria Orbai, William Tillett, et al.
The Journal of Rheumatology|September 10, 2009
How to ascertain drug safety in the context of benefit. Controversies and concernsLee S Simon, C Vibeke Strand, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schemaMarissa N Lassere, Kent R Johnson, Maarten Boers, et al.
Plos One|May 29, 2019
New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II studyMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Pageof 57